To develop OliX’s OLX75016 candidate primarily targeting metabolic-associated steatohepatitis (MASH).
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback